Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments (Q43752527)

26 November 2017

Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments (English)

1 reference

cost-effectiveness analysis

26 November 2017

0 references

1 reference

5

1 reference

26 November 2017

Redekop WK

1

1 reference

26 November 2017

Stolk EA

2

1 reference

26 November 2017

Kok E

3

1 reference

26 November 2017

Lovas K

4

1 reference

26 November 2017

Busschbach JJ

6

1 reference

26 November 2017

1 December 2004

1 reference

26 November 2017

Diabetes and Metabolism

1 reference

26 November 2017

30

1 reference

26 November 2017

6

1 reference

26 November 2017

549-556

1 reference

The burden of diabetic foot ulcers

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Diabetic foot ulcers: a quality of life issue

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

The cost effectiveness of Apligraf treatment of diabetic foot ulcers.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Modeling valuations for EuroQol health states

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

The dysvascular foot: a system for diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Diabetic foot ulcers in a multidisciplinary setting. An economic analysis of primary healing and healing with amputation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Cost-effective management of diabetic foot ulcers. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

An Experimental Test of a Theoretical Foundation for Rating-scale Valuations

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Cost utility analysis of sildenafil compared with papaverine-phentolamine injections

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Validity and feasibility of the use of condition-specific outcome measures in economic evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Valuing health-related quality of life in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Quality of life associated with diabetes mellitus in an adult population.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Health state preference assessment in diabetic peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

A new explanation for the difference between time trade-off utilities and standard gamble utilities

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Whose quality of life? or Whose decision?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

Importance of differentiating health status from quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970154-4

7 January 2021

10.1016/S1262-3636(07)70154-4

Identifiers

DOI

1 reference

26 November 2017

1 reference